Glucosamine and Chondroitin Effects
GLANCE
1 other identifier
interventional
20
1 country
1
Brief Summary
A common starting dose of glucosamine and chondroitin will reduce inflammation as reflected by a reduction in serum C-reactive protein.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2012
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2012
CompletedFirst Submitted
Initial submission to the registry
September 4, 2012
CompletedFirst Posted
Study publicly available on registry
September 11, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2013
CompletedMay 28, 2014
May 1, 2014
11 months
September 4, 2012
May 23, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
hsCRP
hsCRP is a biomarker of systemic inflammation
1 year
Secondary Outcomes (1)
untargeted (exploratory) serum metabolomics (differences in small molecule abundance ratios)
1 year
Study Arms (2)
Glucosamine and Chondroitin
EXPERIMENTALGlucosamine and Chondroitin
Placebo
PLACEBO COMPARATORInactive ingredients
Interventions
Glucosamine (1500 mg) and Chondroitin (1200 mg)
Eligibility Criteria
You may qualify if:
- Healthy
- Overweight (body mass index kg/m2 (BMI) between 25 and 32.5)
- Non-smoking men and women
- Aged 20-55y
You may not qualify if:
- Chronic medical illness, history of gastrointestinal, hepatic, or renal disorders, or inflammatory conditions (including autoimmune and inflammatory diseases)
- Pregnancy or lactation
- Currently on a weight-loss diet
- BMI (body mass index) \< 25 or \> 30
- Alcohol intake of greater than 2 drinks/day
- Current use of prescription or over-the-counter medications, (Excluding oral contraceptives and hormone-secreting IUDs), including use of aspirin or NSAIDs more than 2 days per week
- Abnormal renal, liver or metabolic test
- Inability to swallow pills
- Known allergy to shellfish
- Not willing to take pills made from shellfish or animal sources
- Intention to relocate out of study area within next 4 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
Related Publications (1)
Navarro SL, White E, Kantor ED, Zhang Y, Rho J, Song X, Milne GL, Lampe PD, Lampe JW. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One. 2015 Feb 26;10(2):e0117534. doi: 10.1371/journal.pone.0117534. eCollection 2015.
PMID: 25719429DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 4, 2012
First Posted
September 11, 2012
Study Start
September 1, 2012
Primary Completion
August 1, 2013
Study Completion
August 1, 2013
Last Updated
May 28, 2014
Record last verified: 2014-05